Stock A082800 VIVOZON PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Vivozon Pharmaceutical Co., Ltd.

Equities

A082800

KR7082800004

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
2,885 KRW +1.05% Intraday chart for Vivozon Pharmaceutical Co., Ltd. +1.23% -3.83%
2023 Tranche Update on Vivozon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 19, 2023. CI
2023 Vivozon Pharmaceutical Co., Ltd.'s Equity Buyback announced on September 19, 2023, has closed with 5,000,000 shares. CI

Business Summary

Vivozon Pharmaceutical Co Ltd , formerly Vivozon Healthcare Inc, is a Korea-based company mainly engaged in the manufacture and sale of finished pharmaceutical products. The Company operates its business through three segments. The Pharmaceutical Business segment is engaged in the manufacture and sale of finished medicines such as external skin preparations, antipyretic analgesic, anti-inflammatory drugs and antidiabetic drugs. The Optical Business segment is engaged in the manufacture and sale of finished products and lighting module sets such as general lighting and automotive lighting using light emitting diode (LED) light sources. The Cosmetics Business segment is engaged in the manufacture and sale of cosmetics and cosmetic ingredients.

Number of employees: 238

Sales per Business

KRW in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
51,642 87.4 % 71,318 100.0 % +38.10%

Sales per region

KRW in Million2022Weight2023Weight Delta
South Korea
96.1 %
54,624 92.5 % 68,514 96.1 % +25.43%
Others
1.7 %
2,380 4.0 % 1,227 1.7 % -48.44%
China
1.2 %
449 0.8 % 886 1.2 % +97.42%
Russia
0.4 %
218 0.4 % 277 0.4 % +27.08%
Japan
0.4 %
1,073 1.8 % 264 0.4 % -75.39%
Vietnam
0.2 %
323 0.5 % 149 0.2 % -53.85%

Managers

Managers TitleAgeSince
Dong-Hoon Oh CEO
 Chief Executive Officer 52 -
Jae-Gwan Han CEO
 Chief Executive Officer 58 13-07-31
Seung-Rak Hong DFI
 Director of Finance/CFO 51 -
Chan-Hui Han AUD
 Comptroller/Controller/Auditor 60 -

Members of the board

Members of the board TitleAgeSince
Jae-Gwan Han CEO
 Chief Executive Officer 58 13-07-31
Yoon-Chul Lee BRD
 Director/Board Member 53 20-01-19
Dong-Hoon Oh CEO
 Chief Executive Officer 52 -
Byung-Gi Kim BRD
 Director/Board Member 55 -
Hyun-Seok Lee BRD
 Director/Board Member 52 -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 48,211,715 29,868,662 ( 61.95 %) 1,005,281 ( 2.085 %) 61.95 %

Shareholders

NameEquities%Valuation
Doo-hyun Lee
27.55 %
13,284,302 27.55 % 34 M ₩
Vivozon, Inc.
9.498 %
4,579,229 9.498 % 12 M ₩
KTB Network Co., Ltd. (Venture Capital)
0.2127 %
102,533 0.2127 % 261 616 ₩
Synergy IB Investment Co., Ltd.
0.1659 %
79,999 0.1659 % 204 120 ₩
Boo-hwan Jang
0.0270 %
13,034 0.0270 % 33 257 ₩
Im-ho Lee
0.0205 %
9,861 0.0205 % 25 161 ₩
Hyun-Min Lee
0.0197 %
9,495 0.0197 % 24 227 ₩
Han-Soo Park
0.006223 %
3,000 0.006223 % 7 655 ₩
Eung-seop Choi
0.006223 %
3,000 0.006223 % 7 655 ₩
DFA Australia Ltd.
0.003091 %
1,490 0.003091 % 3 802 ₩

Company contact information

Vivozon Pharmaceutical Co., Ltd.

15 Samin-ro Namsa-eup

17118, Yongin

+

http://www.vivozonpharm.com
address Vivozon Pharmaceutical Co., Ltd.(A082800)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Sector Other Pharmaceuticals

1st Jan change Capi.
VIVOZON PHARMACEUTICAL CO., LTD. Stock Vivozon Pharmaceutical Co., Ltd.
-3.83% 101M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A082800 Stock
  4. Company Vivozon Pharmaceutical Co., Ltd.